Nuvation Bio (NUVB) said Monday the US Food and Drug Administration has accepted its new drug application for drug candidate taletrectinib intended for the treatment of non-small cell lung cancer.
The FDA granted priority review and set a Prescription Drug User Fee Act goal date of June 23, Nuvation said.
Nuvation stock was up more than 4% in recent premarket activity.
Price: 2.80, Change: +0.12, Percent Change: +4.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.